Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000689744 | SCV000817410 | uncertain significance | Bloom syndrome | 2024-01-11 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 1174 of the BLM protein (p.Gly1174Arg). This variant is present in population databases (rs776156059, gnomAD 0.003%). This missense change has been observed in individual(s) with male breast cancer (PMID: 30613976). ClinVar contains an entry for this variant (Variation ID: 569178). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt BLM protein function with a positive predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002458221 | SCV002617888 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-01-25 | criteria provided, single submitter | clinical testing | The p.G1174R variant (also known as c.3520G>A), located in coding exon 17 of the BLM gene, results from a G to A substitution at nucleotide position 3520. The glycine at codon 1174 is replaced by arginine, an amino acid with dissimilar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000689744 | SCV002090579 | uncertain significance | Bloom syndrome | 2018-07-06 | no assertion criteria provided | clinical testing |